Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Sulfate in TTP (MAGMAT)
NCT03237819Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thrombotic thrombocytopenic purpura (TTP) comparing Magnesium Sulfate with Placebo (2 arms). Primary endpoint: Time to normalization of the platelet count at 3 months. Status: unknown.
02
Drugs
magnesium sulfate
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT03237819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237819.